Direct costs of relapses in patients with relapsing-remitting multiple sclerosis-Reference-Cited by-同舟云学术

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis

Published:2021-07 Issue:3 Volume:1 Page:160-169
ISSN:2667-0496
Container-title:Neurology Perspectives
language:es
Short-container-title:Neurology Perspectives

Author:

Casado V.,Bonaventura I.,Brieva L.,Martínez-Yélamos S.,Martín G.,Presas-Rodriguez S.,Hervas M.,Hernández J.J.,Munteis E.,Escartin A.,Gubieras L.,Mañé-Martínez M.A.,Ramió-Torrentà L.

Funder

Novartis Farmacéutica SA

Publisher

Elsevier BV

Subject

General Earth and Planetary Sciences,General Engineering,General Environmental Science

Reference31 articles.

1. Multiple sclerosis and other demyelinating diseases;Hauser,1994

2. The costs of a multiple sclerosis relapse in Catalonia (Spain);Casado;Neurologia.,2006

3. Epidemiología de la esclerosis múltiple en España;Pérez-Carmona;RevNeurol.,2019

4. Improving compliance with interferon-beta therapy in patients with multiple sclerosis;Portaccio;CNS Drugs,2009

5. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis;Yang;J Med Econ,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain;PharmacoEconomics - Open;2023-02-21

2. Cost–effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain;Journal of Comparative Effectiveness Research;2023-02